ISU Abxis Co., Ltd.

A086890

KR7086890001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-03 EDT			5-day change	1st Jan Change
6,580 ^KRW	+1.70%		-0.75%	+8.76%

2023	ISU Abxis Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence	CI

ISU Abxis Co., Ltd. announced that it has received KRW 80 billion in funding

June 29, 2021

On June 30, 2021, ISU Abxis Co., Ltd. (KOSDAQ:A086890) closed the transaction.

Latest news about ISU Abxis Co., Ltd.

ISU Abxis Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Eucure Biopharma Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence	22-10-31	CI
ISU Abxis Co., Ltd. announced that it has received KRW 80 billion in funding	21-06-29	CI
ISU Abxis Co., Ltd. announced that it expects to receive KRW 80 billion in funding	21-06-27	CI
A group of buyers acquired 5.8% stake of ISU Abxis Co., Ltd. from Saneun Capital Co., Ltd. for KRW 17.1 billion.	20-09-21	CI
ISU Abxis Co., Ltd. announced that it has received KRW 40 billion in funding	19-04-11	CI
ISU Abxis Co., Ltd. announced that it expects to receive KRW 40 billion in funding	19-02-20	CI
ISU ABXIS Co., Ltd. announced that it expects to receive KRW 20 billion in funding	17-11-30	CI
Catalyst Biosciences, Inc. and ISU Abxis to Initiate Phase I/II hemophilia B study	17-04-10	CI
ISU ABXIS Co., Ltd. Appoints Lee Seok Ju as Chief Executive Officer	17-03-25	CI
ISU ABXIS Co., Ltd.(KOSDAQ:A086890) added to S&P Global BMI Index	16-09-19	CI
Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration	13-10-09	CI
Isu Abxis Co. Ltd announced that it has received KRW 12 billion in funding.	12-05-25	CI
Isu Abxis Co. Ltd announced that it expects to receive KRW 12 billion in funding.	12-05-23	CI

ISU Abxis Co., Ltd. is a Korea-based company mainly engaged in the biopharmaceutical business. The Company operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6,580 KRW

Average target price

8,000 KRW

Spread / Average Target

+21.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ISU ABXIS CO., LTD.	+8.76%	168M
CSL LIMITED	-1.62%	90.85B
SAMSUNG BIOLOGICS CO.,LTD.	-0.92%	39.02B
BIOGEN INC.	-9.57%	33.46B
BIOMARIN PHARMACEUTICAL INC.	-17.98%	14.51B
INCYTE CORPORATION	-6.74%	13.22B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.76%	11.65B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-47.31%	10.57B
SWEDISH ORPHAN BIOVITRUM AB	+6.52%	9.23B
ALTEOGEN INC.	+137.06%	7.71B

Biopharmaceuticals

ISU Abxis Co., Ltd.

Equities

A086890

KR7086890001

Pharmaceuticals

ISU Abxis Co., Ltd. announced that it has received KRW 80 billion in funding

Latest news about ISU Abxis Co., Ltd.

Chart ISU Abxis Co., Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals